Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib. Issue 9 (13th January 2015)

• Record Type: Journal Article
• Authors: Reichardt, Peter; Kang, Yoon‐Koo; Rutkowski, Piotr; Schuette, Jochen; Rosen, Lee S.; Seddon, Beatrice; Yalcin, Suayib; Gelderblom, Hans; Williams, Charles C.; Fumagalli, Elena; Biasco, Guido; Hurwitz, Herbert I.; Kaiser, Pamela E.; Fly, Kolette; Matczak, Ewa; Chen, Liang; Lechuga, Maria José; Demetri, George D.
• Is Part Of: Cancer. Volume 121:Issue 9(2015)
• Page Start: 1405
• Page End: 1413
• Publication Date: 2015-01-13
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29220
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29220-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>The objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with advanced GIST after imatinib failure.</p> </sec> <sec id="cncr29220-sec-0002" sec-type="section"> <title>METHODS</title> <p>Imatinib‐resistant/intolerant patients with advanced GIST received sunitinib on an initial dosing schedule of 50 mg daily in 6‐week cycles (4 weeks on treatment, 2 weeks off treatment). Tumor assessment frequency was according to local practice, and response was assessed by investigators according to Response Evaluation Criteria in Solid Tumors version 1.0. Overall survival (OS) and safety were assessed regularly. Post hoc analyses evaluated different patterns of treatment management.</p> </sec> <sec id="cncr29220-sec-0003" sec-type="section"> <title>RESULTS</title> <p>At final data cutoff, 1124 patients comprised the intent‐to‐treat population, and 15% of these patients had a baseline Eastern Cooperative Oncology Group performance status ≥2. The median treatment duration was 7.0 months. The median time to tumor progression was 8.3 months (95% confidence interval [CI], 8.0‐9.4 months), the median OS was 16.6 months (95% CI, 14.9‐18.0 months), and 36% of patients were alive at the time of analysis. Patients for whom the initial dosing schedule was modified exhibited longer median OS (23.5 months) than those who were treated strictly according to the initial dosing schedule (11.1 months). The most common treatment‐related grade 3 and 4 adverse events were hand‐foot syndrome (11%), fatigue (9%), neutropenia (8%), hypertension (7%), and thrombocytopenia (6%). Treatment‐related adverse events associated with cardiac function (eg, congestive heart failure and myocardial infarction) were reported at frequencies of ≤1% each.</p> </sec> <sec id="cncr29220-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>This treatment‐use study confirms the long‐term safety and efficacy of sunitinib in a large international population of patients with advanced GIST after imatinib failure. <bold><italic>Cancer</italic> 2015;121:1405–1413.</bold> © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>